Tg Therapeutics (TGTX) Amortization of Deferred Charges (2011 - 2026)
Tg Therapeutics (TGTX) posted quarterly Amortization of Deferred Charges of $285000.0 for Q1 2026, down 6.25% year-over-year from $304000.0 in Q1 2025, and down 34.03% quarter-over-quarter from $432000.0 in Q4 2025.
Powered by 
Analysis
Tg Therapeutics (TGTX) Amortization of Deferred Charges (2011 - 2026) Analysis & Trends
Tg Therapeutics' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $285000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 6.25% year-over-year to $285000.0; the TTM figure through Mar 2026 stood at $1.7 million (down 63.81% YoY), while the FY2025 annual figure was $1.7 million, down 8.0% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $285000.0, down from $432000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $4.0 million in Q3 2024, with the low at $208000.0 in Q4 2024.
- The 5-year median for Amortization of Deferred Charges is $500000.0 (2022), against an average of $737882.4.
- The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges jumped 566.67% in 2024, then plunged 89.22% in 2025.
- Tg Therapeutics' Amortization of Deferred Charges stood at $1.3 million in 2022, then tumbled by 32.06% to $905000.0 in 2023, then tumbled by 77.02% to $208000.0 in 2024, then jumped by 107.69% to $432000.0 in 2025, then sank by 34.03% to $285000.0 in 2026.
- Business Quant data shows TGTX's Amortization of Deferred Charges at $285000.0 in Q1 2026, $432000.0 in Q4 2025, and $431000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Tg Therapeutics | 7.97 Bn | 7.29 Bn | 199.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 232,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 304,000.00 |
| Sep 30, 2025 | 304,000.00 |
| Jun 30, 2025 | 304,000.00 |
| Mar 31, 2025 | 304,000.00 |
| Dec 31, 2024 | 308,000.00 |
| Sep 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 639,000.00 |
| Mar 31, 2024 | 639,000.00 |
| Dec 31, 2023 | 661,000.00 |
| Sep 30, 2023 | 600,000.00 |
| Jun 30, 2023 | 639,000.00 |
| Mar 31, 2023 | 461,000.00 |
| Dec 31, 2022 | 461,000.00 |
| Sep 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 500,000.00 |
| Mar 31, 2022 | 461,000.00 |
| Dec 31, 2021 | 386,000.00 |
| Sep 30, 2021 | 300,000.00 |